French pre-clinical biotech Mablink Biosciences has confirmed earlier rumors that it has agreed to a takeover bid from acquisition-hungry US pharma major Eli Lilly (NYSE: LLY).
The transaction, financial terms of which were not disclosed, is subject to approval from the French Ministry of the Economy. It also marks the sixth M&A deal this year by Lilly.
Lyon-based Mablink is building a pipeline on PSARLink, a linker technology designed to reduce systemic toxicity and increase the amount of the therapeutic payload delivered to target cancer cells.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze